<DOC>
	<DOCNO>NCT02236169</DOCNO>
	<brief_summary>The objective study determine pharmacokinetic comparability 84 µg ipratropium bromide HFA-134a inhalation aerosol 84 µg ATROVENT® CFC Inhalation Aerosol COPD patient</brief_summary>
	<brief_title>Trial Determine Comparability Ipratropium Bromide Hydrofluoroalkane ( HFA ) -134a Inhalation Aerosol ATROVENT® Chlorofluorocarbon ( CFC ) Inhalation Aerosol , Patients With Chronic Obstructive Pulmonary Disease ( COPD )</brief_title>
	<detailed_description />
	<mesh_term>Lung Diseases</mesh_term>
	<mesh_term>Lung Diseases , Obstructive</mesh_term>
	<mesh_term>Pulmonary Disease , Chronic Obstructive</mesh_term>
	<mesh_term>Respiratory Aspiration</mesh_term>
	<mesh_term>Chronic Disease</mesh_term>
	<mesh_term>Ipratropium</mesh_term>
	<mesh_term>Bromides</mesh_term>
	<criteria>All patient must diagnosis COPD must meet follow spirometric criterion : Patients must stable , moderate severe airway obstruction Forced Expiratory Volume one second ( FEV1 ) &lt; =65 % predict normal FEV1 &lt; =70 % Forced vital capacity ( FVC ) Males : Predicted Normal FEV1 = 0.093 ( height inch ) 0.032 ( age ) 1.343 Females : Predicted Normal FEV1 = 0.085 ( height inch ) 0.025 ( age ) 1.692 Male female age 40 year old Patients must smoke history 10 packyears . A packyear defined equivalent smoke one pack cigarettes ( 20 cigarette ) per day year Patients must able satisfactorily administer medication , perform pulmonary function test ( PFTs ) maintain record study period require protocol All patient must sign Informed Consent Form prior participation trial ( i.e. , prior prestudy washout usual pulmonary medication prior fast laboratory test ) Patients significant disease COPD exclude . A significant disease define disease opinion investigator may either put patient risk participation study disease may influence result study patient ability participate study Patients clinically relevant baseline hematology , blood chemistry urinalysis . If abnormality defines disease list exclusion criterion patient exclude All patient serum glutamic oxaloacetic transaminase ( SGOT ) &gt; 80 IU/L , serum glutamic pyruvic transaminase ( SGPT ) &gt; 80 IU/L , bilirubin &gt; 2.0 mg/dl , creatinine &gt; 2.0 mg/dl exclude regardless clinical condition . Repeat laboratory evaluation conduct patient Patients history asthma , allergic rhinitis atopy blood eosinophil count 600/mm3 . A repeat eosinophil count conduct patient Patients recent ( i.e. , one year less ) history myocardial infarction Patients recent history ( i.e. , three year less ) cardiac failure , patient cardiac arrhythmia require therapy , patient receive systemic betablockers patient chronic daytime oxygen therapy Patients know active tuberculosis Patients history cancer within last 5 year . Patients treat basal cell carcinoma allow Patients history lifethreatening pulmonary obstruction , history cystic fibrosis bronchiectasis Patients undergone thoracotomy pulmonary resection . Patients history thoracotomy reason evaluate per exclusion criterion No.1 Patients upper respiratory tract infection COPD exacerbation 6 week prior screen visit ( Visit 1 ) baseline period Patients known hypersensitivity anticholinergic drug Patients know symptomatic prostatic hypertrophy bladderneck obstruction Patients know narrowangle glaucoma Patients cromolyn sodium nedocromil sodium Patients antihistamines Pregnant nursing woman woman childbearing potential use medically approve mean contraception ( e.g. , oral contraceptive , intrauterine device , diaphragm Norplant® ) Patients take investigational drug within 1 month 6 halflives ( whichever longer ) drug prior screen visit patient currently enrol another research study Patients history and/or active alcohol drug abuse</criteria>
	<gender>All</gender>
	<minimum_age>40 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2014</verification_date>
</DOC>